Eohilia is the first and only 12-week, fda-approved oral treatment designed for people with eosinophilic esophagitis (eoe) 11 years and older. It is a liquid-like form of budesonide specifically … Eohilia is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (eoe).

Eohiliaâ„¢ (budesonide oral suspension) is an fda approved 12-week oral treatment for eoe in people 11 years and older. It has not been shown to be safe and effective for longer than 12 weeks.